WO2002076393A3 - Antiagionecic, antitumor, chemopreventative agents - Google Patents

Antiagionecic, antitumor, chemopreventative agents Download PDF

Info

Publication number
WO2002076393A3
WO2002076393A3 PCT/US2002/008852 US0208852W WO02076393A3 WO 2002076393 A3 WO2002076393 A3 WO 2002076393A3 US 0208852 W US0208852 W US 0208852W WO 02076393 A3 WO02076393 A3 WO 02076393A3
Authority
WO
WIPO (PCT)
Prior art keywords
type compound
magnolol
honokiol
conditions
antiagionecic
Prior art date
Application number
PCT/US2002/008852
Other languages
French (fr)
Other versions
WO2002076393A2 (en
Inventor
Jack L Arbiser
Xianhe Bai
Original Assignee
Univ Emory
Jack L Arbiser
Xianhe Bai
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Emory, Jack L Arbiser, Xianhe Bai filed Critical Univ Emory
Priority to AU2002336020A priority Critical patent/AU2002336020A1/en
Priority to US10/472,512 priority patent/US20040105906A1/en
Publication of WO2002076393A2 publication Critical patent/WO2002076393A2/en
Publication of WO2002076393A3 publication Critical patent/WO2002076393A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Abstract

Pharmaceutical compositions and methods of treating conditions such as angiogenic-, neoplastic-, and cancer-related conditions and skin conditions are disclosed. The methods include administering to a host in need of treatment an effective amount of at least one honokiol-type compound and/or at least one magnolol-type compound. In addition, the pharmaceutical compositions include at least one honokiol-type compound and/or at least one magnolol-type compound in combination with a pharmaceutically acceptable carrier. The honokiol-type compound and/or magnolol-type compound are present in a dosage level effective to treat conditions listed above.
PCT/US2002/008852 2001-03-23 2002-03-22 Antiagionecic, antitumor, chemopreventative agents WO2002076393A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU2002336020A AU2002336020A1 (en) 2001-03-23 2002-03-22 Antiagionecic, antitumor, chemopreventative agents
US10/472,512 US20040105906A1 (en) 2002-03-22 2002-03-22 Antiagionecic, antitumor, chemopreventative agents

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US27814901P 2001-03-23 2001-03-23
US60/278,149 2001-03-23

Publications (2)

Publication Number Publication Date
WO2002076393A2 WO2002076393A2 (en) 2002-10-03
WO2002076393A3 true WO2002076393A3 (en) 2003-04-03

Family

ID=23063861

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2002/008852 WO2002076393A2 (en) 2001-03-23 2002-03-22 Antiagionecic, antitumor, chemopreventative agents

Country Status (2)

Country Link
AU (1) AU2002336020A1 (en)
WO (1) WO2002076393A2 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101223120A (en) * 2005-02-23 2008-07-16 杰克·L·阿比瑟 Honokiol derivatives for the treatment of proliferative disorders
AU2008247856A1 (en) * 2007-05-03 2008-11-13 Arbiser, Jack Honokiol analogs and their use in treating cancers
DE102009048044A1 (en) * 2009-10-02 2011-04-21 Beiersdorf Ag Use of magnolol or honokiol as antibacterial, antimycotic, antiparasitic or antiviral agents
CN110950773B (en) * 2018-09-27 2021-05-25 湖南大学 Biphenyldiphenol amide derivative and application thereof as anticancer drug
CN109589409A (en) * 2018-12-19 2019-04-09 天津中新药业集团股份有限公司乐仁堂制药厂 Pharmaceutical combination preparations and magnolol are preparing the application in chemotherapeutics Synergy and attenuation agent
CN110812345A (en) * 2019-12-13 2020-02-21 四川大学华西医院 Application of honokiol in preparation of medicine for treating and/or preventing rosacea

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5135746A (en) * 1989-04-25 1992-08-04 Takeda Chemical Industries, Ltd. Control of protozoal disease

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5135746A (en) * 1989-04-25 1992-08-04 Takeda Chemical Industries, Ltd. Control of protozoal disease

Also Published As

Publication number Publication date
AU2002336020A1 (en) 2002-10-08
WO2002076393A2 (en) 2002-10-03

Similar Documents

Publication Publication Date Title
AU747599C (en) Antitumor agents
NO20014842D0 (en) Docet shaft in combination with rhuMAb HER2 for the treatment of cancer
WO2002056912A3 (en) Pharmaceutical combination for the treatment of cancer containing a 4-quinazolineamine and another anti-neoplastic agent
MXPA04006039A (en) Methods for the treatment of peripheral neural and vascular ailments.
WO2002076472A3 (en) Pharmaceutical combinations for the treatment of cancer comprising dioxolane nucleoside analogs
EP2295063A3 (en) Compositions and the use thereof the treatment of mitochondrial diseases
WO2004062604A3 (en) Treatment of cancer with 2-deoxyglucose
WO2004002999A3 (en) Modified 2' and 3' -nucleoside produgs for treating flaviridae infections
WO2007062093A3 (en) Combination therapy for the treatment of cancer comprising a metalloprotease inhibitor
WO2002078627A3 (en) N-acetylcysteine compositions and methods for the treatment and prevention of drug toxicity
WO2001030802A3 (en) Therapeutic treatments comprising administration of certain steroids for blood cell deficiencies
WO2001068125A3 (en) Methods and compositions for the treatment and prevention of erectile dysfunction
WO2005025501A3 (en) Co-administration of polysaccharide with a chemotherapeutic agent for the treatment of cancer
WO2001010387A3 (en) Antiviral therapy use of P-glycoprotein modulators
IL147489A0 (en) Use of docetaxel for treating hepatocellular carcinoma
EP1383516A4 (en) Co-administration of a polysaccharide with a chemotherapeutic agent for the treatment of cancer
WO2002076393A3 (en) Antiagionecic, antitumor, chemopreventative agents
WO2003026570A3 (en) Reduced toxicity cisplatin formulations and methods for using the same
WO2002076400A3 (en) Inosine compounds and their use for treating or preventing an inflamation or a reperfusion disease
WO2006091222A3 (en) Methods of treating and preventing severe acute respiratory syndrome (sars) with avr118
WO2002076405A3 (en) Compositions and methods of treatment of ulcerating diseases, burns, and related conditions
HK1061530A1 (en) The use of n-acetyl-d-glucosamine in the manufacture of pharmaceutical useful for supressing side-effect of radiotherapy and chemotherapy.
WO2003032895A3 (en) Methods and pharmaceutical compositions for stimulating the immune system and/or treating cancer
MXPA05003633A (en) 2" oxo-voruscharin and derivatives thereof.
WO2003000182A3 (en) Ppar-alpha ligands for the treatment or prevention of cachexia

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AU CA JP US

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 10472512

Country of ref document: US

122 Ep: pct application non-entry in european phase
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP